PureTech’s LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300.